Judy Carmody, Ph.D.

Biography

Judy Carmody, Ph.D., is the founder and Principal Consultant of Carmody Quality Solutions, LLC. a dynamic, innovative quality solutions provider to life science startups and global Fortune 500 organizations who are as passionate as we are about keeping patients safe and delivering quality products. 

Dr. Carmody is the former president of Avatar Pharmaceutical Services, a GMP, FDA-registered contract research organization and manufacturer which was acquired by Vertex Pharmaceuticals in 2010. Since then she has held senior level positions in small and large pharma and has strengthened her knowledge of robust quality systems. With each custom-crafted solution she fulfills her vision of connecting everyday quality processes and procedures with the strategic needs of her client's business.

Prior to founding Avatar, Dr. Carmody spent 10 years in the (bio)pharmaceutical industry, developing methods for small molecules and oligonucleotides, managing QC, Analytical, and Validation groups. In addition to this solid grounding in pharmaceuticals, she worked at Waters Corporation's Applied Technology and Marketing groups where she developed novel separations methods with colleagues and (bio)pharmaceutical customers. At Waters, Dr. Carmody brought numerous new technologies to market through published papers and technical presentations both at world-wide conferences and leading (bio)pharmaceutical companies.

Scientific understanding underscores Dr. Carmody’s unique approach to solving the most challenging Quality or Analytical issues. A resume that spans roles in applied technology, marketing, bench chemistry, validation, quality management and several leadership roles provides the basis of Dr. Carmody’s approach to developing solutions. Her experience leverages the creative integration of technologies from diverse fields and enables these elements to be transformed into client solutions. 

Dr. Carmody holds a Ph.D. in Analytical Chemistry from Clark University in Worcester, Massachusetts.



PUBLICATIONS:

1. The FDA Group’s Insider Newsletter. “Discussing FDA Proposed Pharma Quality Metrics, Device Cybersecurity Recommendations + Warning Letter.” September, 2022.
2. American Pharmaceutical Review. “Assuring the Quality of Oligonucleotide APIs and DPs.” May/June, 2022.
3. BioProcess Online. “How ‘Two People With A Molecule’ Can Build A Quality Culture.” December, 2019.
4. Pharmaceutical Online. “Think A Quality Culture Doesn’t Affect Your Bottom Line? Think Again.” September, 2019.
5. Clinical Leader. “Employing GMP Techniques In GCP For More Robust, Compliant Clinical Studies.” June, 2018.
6. BioProcess Online. “How To Optimize Your Stability Program At Each Phase Of Drug Development.” April, 2017.